Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients
- 15 August 2008
- journal article
- ssat plenary-presentation
- Published by Elsevier BV in Journal of Gastrointestinal Surgery
- Vol. 12 (10), 1738-1744
- https://doi.org/10.1007/s11605-008-0646-0
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Infliximab in Ulcerative Colitis is Associated with an Increased Risk of Postoperative Complications After Restorative ProctocolectomyDiseases of the Colon & Rectum, 2008
- Biological therapies in inflammatory bowel disease: top-down or bottom-up?Current Opinion in Gastroenterology, 2007
- Patient Preferences Between Surgical and Medical Treatment in Crohn's DiseaseDiseases of the Colon & Rectum, 2007
- Effect of Infliximab on Short-Term Complications in Patients Undergoing Operation for Chronic Ulcerative ColitisJournal of the American College of Surgeons, 2007
- Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel DiseasesGastroenterology Clinics of North America, 2006
- Toxicity of infliximab in the course of treatment of Crohn’s diseaseExpert Opinion on Drug Safety, 2005
- Recurrence after segmental resection for colonic Crohn's diseaseBritish Journal of Surgery, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Medical therapy for Crohn’s diseaseCurrent Opinion in Gastroenterology, 1999
- The resectional reoperation rate for Crohn's disease in a general community hospitalDiseases of the Colon & Rectum, 1983